<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32174778</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>11</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>11</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1449-1907</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>4</Issue><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>International journal of medical sciences</Title><ISOAbbreviation>Int J Med Sci</ISOAbbreviation></Journal><ArticleTitle>Identification of VGF nerve growth factor inducible-producing cells in human spinal cords and expression change in patients with amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>480</StartPage><EndPage>489</EndPage><MedlinePgn>480-489</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7150/ijms.39101</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a serious disease characterized by the degeneration of motor neurons resulting in muscle weakness and paralysis. The neuroendocrine polypeptide VGF is localized in the central nervous system and peripheral endocrine neurons and is cleaved into several polypeptides with multiple functions. Previous studies revealed that VGF was decreased in the cerebrospinal fluid of ALS model mice and sporadic ALS patients. However, it is unknown which cells supply VGF in the spinal cord and a detailed localization is lacking. In this study, we evaluated the VGF-producing cells and protein localization using <i>in situ</i> hybridization and immunostaining in the spinal cords of ALS and control patients. <i>VGF</i> mRNA was localized both in the dorsal and anterior horns of the spinal cords. Moreover, in the anterior horn, <i>VGF</i> mRNA co-localized with a neurofilament heavy chain, which is a motor neuron marker, and <i>VGF</i> mRNA-positive motor neurons were decreased in the spinal cords of ALS patients. We revealed that VGF protein level was decreased in the anterior horn of ALS patients; however, the expression level of VGF protein was not changed in the posterior horn or white matter. Furthermore, the expression level of VGF protein was conserved in ALS patients with long-term survival. These results reveal that VGF is mainly supplied by human motor neurons, and suggest that VGF expression changes may be involved in ALS pathology.</AbstractText><CopyrightInformation>&#xa9; The author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Noda</LastName><ForeName>Yasuhiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu 501-1196, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Miruto</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu 501-1196, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Shinsuke</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu 501-1196, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ito</LastName><ForeName>Junko</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pathology, Brain Research Institute, Niigata University, Niigata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kakita</LastName><ForeName>Akiyoshi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathology, Brain Research Institute, Niigata University, Niigata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hara</LastName><ForeName>Hideaki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu 501-1196, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimazawa</LastName><ForeName>Masamitsu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu 501-1196, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>02</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Int J Med Sci</MedlineTA><NlmUniqueID>101213954</NlmUniqueID><ISSNLinking>1449-1907</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009414">Nerve Growth Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C510637">VGF protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017403" MajorTopicYN="N">In Situ Hybridization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009414" MajorTopicYN="N">Nerve Growth Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">VGF nerve growth factor inducible</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">motor neuron</Keyword></KeywordList><CoiStatement>Competing Interests: The authors have declared that no competing interest exists.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32174778</ArticleId><ArticleId IdType="pmc">PMC7053308</ArticleId><ArticleId IdType="doi">10.7150/ijms.39101</ArticleId><ArticleId IdType="pii">ijmsv17p0480</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vande Velde C, Dion PA, Rouleau GA. Amyotrophic lateral sclerosis: new genes, new models, and new mechanisms. F1000 biology reports. 2011;3:18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3169903</ArticleId><ArticleId IdType="pubmed">21941597</ArticleId></ArticleIdList></Reference><Reference><Citation>Niccoli T, Partridge L, Isaacs AM. Ageing as a risk factor for ALS/FTD. Human molecular genetics. 2017;26:R105&#x2013;R113.</Citation><ArticleIdList><ArticleId IdType="pubmed">28977441</ArticleId></ArticleIdList></Reference><Reference><Citation>Levi A, Eldridge JD, Paterson BM. Molecular cloning of a gene sequence regulated by nerve growth factor. Science (New York, NY. 1985;229:393&#x2013;395.</Citation><ArticleIdList><ArticleId IdType="pubmed">3839317</ArticleId></ArticleIdList></Reference><Reference><Citation>Trani E, Giorgi A, Canu N, Amadoro G, Rinaldi AM, Halban PA. et al. Isolation and characterization of VGF peptides in rat brain. Role of PC1/3 and PC2 in the maturation of VGF precursor. Journal of neurochemistry. 2002;81:565&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pubmed">12065665</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamura H, Tanaka M, Kanemasa K, Ban Y, Inouye ST, Ibata Y. In situ hybridization histochemistry of vgf mRNA in the rat suprachiasmatic nucleus: co-localization with vasopressin/neurophysin and VIP/PHI. Neuroscience letters. 1995;189:181&#x2013;184a.</Citation><ArticleIdList><ArticleId IdType="pubmed">7603615</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder SE, Peng B, Pintar JE, Salton SR. Expression of VGF mRNA in developing neuroendocrine and endocrine tissues. The Journal of endocrinology. 2003;179:227&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pubmed">14596674</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato H, Fukutani Y, Yamamoto Y, Tatara E, Takemoto M, Shimamura K. et al. Thalamus-derived molecules promote survival and dendritic growth of developing cortical neurons. J Neurosci. 2012;32:15388&#x2013;15402.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6621586</ArticleId><ArticleId IdType="pubmed">23115177</ArticleId></ArticleIdList></Reference><Reference><Citation>Alder J, Thakker-Varia S, Bangasser DA, Kuroiwa M, Plummer MR, Shors TJ. et al. Brain-derived neurotrophic factor-induced gene expression reveals novel actions of VGF in hippocampal synaptic plasticity. J Neurosci. 2003;23:10800&#x2013;10808.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3374594</ArticleId><ArticleId IdType="pubmed">14645472</ArticleId></ArticleIdList></Reference><Reference><Citation>Behnke J, Cheedalla A, Bhatt V, Bhat M, Teng S, Palmieri A, Neuropeptide VGF Promotes Maturation of Hippocampal Dendrites That Is Reduced by Single Nucleotide Polymorphisms. International journal of molecular sciences; 2017. p. 18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5372628</ArticleId><ArticleId IdType="pubmed">28287464</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahm S, Mizuno TM, Wu TJ, Wisor JP, Priest CA, Kozak CA. et al. Targeted deletion of the Vgf gene indicates that the encoded secretory peptide precursor plays a novel role in the regulation of energy balance. Neuron. 1999;23:537&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pubmed">10433265</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis JE, Brameld JM, Jethwa PH. Neuroendocrine Role for VGF. Frontiers in endocrinology. 2015;6:3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4313783</ArticleId><ArticleId IdType="pubmed">25699015</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasinetti GM, Ungar LH, Lange DJ, Yemul S, Deng H, Yuan X. et al. Identification of potential CSF biomarkers in ALS. Neurology. 2006;66:1218&#x2013;1222.</Citation><ArticleIdList><ArticleId IdType="pubmed">16481598</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z, Lange DJ, Ho L, Bonini S, Shao B, Salton SR. et al. Vgf is a novel biomarker associated with muscle weakness in amyotrophic lateral sclerosis (ALS), with a potential role in disease pathogenesis. International journal of medical sciences. 2008;5:92&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2323610</ArticleId><ArticleId IdType="pubmed">18432310</ArticleId></ArticleIdList></Reference><Reference><Citation>Brancia C, Noli B, Boido M, Boi A, Puddu R, Borghero G. et al. VGF Protein and Its C-Terminal Derived Peptides in Amyotrophic Lateral Sclerosis: Human and Animal Model Studies. PloS one. 2016;11:e0164689.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5063282</ArticleId><ArticleId IdType="pubmed">27737014</ArticleId></ArticleIdList></Reference><Reference><Citation>Brancia C, Noli B, Boido M, Pilleri R, Boi A, Puddu R. et al. TLQP Peptides in Amyotrophic Lateral Sclerosis: Possible Blood Biomarkers with a Neuroprotective Role. Neuroscience. 2018;380:152&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">29588252</ArticleId></ArticleIdList></Reference><Reference><Citation>Mead B, Logan A, Berry M, Leadbeater W, Scheven BA. Paracrine-mediated neuroprotection and neuritogenesis of axotomised retinal ganglion cells by human dental pulp stem cells: comparison with human bone marrow and adipose-derived mesenchymal stem cells. PloS one. 2014;9:e109305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4188599</ArticleId><ArticleId IdType="pubmed">25290916</ArticleId></ArticleIdList></Reference><Reference><Citation>Noda Y, Shimazawa M, Tanaka H, Tamura S, Inoue T, Tsuruma K. et al. VGF and striatal cell damage in in vitro and in vivo models of Huntington's disease. Pharmacology research &amp; perspectives. 2015;3:e00140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4492756</ArticleId><ArticleId IdType="pubmed">26171223</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishihira Y, Tan CF, Hoshi Y, Iwanaga K, Yamada M, Kawachi I. et al. Sporadic amyotrophic lateral sclerosis of long duration is associated with relatively mild TDP-43 pathology. Acta neuropathologica. 2009;117:45&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">18923836</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimazawa M, Tanaka H, Ito Y, Morimoto N, Tsuruma K, Kadokura M. et al. An inducer of VGF protects cells against ER stress-induced cell death and prolongs survival in the mutant SOD1 animal models of familial ALS. PloS one. 2010;5:e15307.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3000345</ArticleId><ArticleId IdType="pubmed">21151573</ArticleId></ArticleIdList></Reference><Reference><Citation>Moss A, Ingram R, Koch S, Theodorou A, Low L, Baccei M. et al. Origins, actions and dynamic expression patterns of the neuropeptide VGF in rat peripheral and central sensory neurones following peripheral nerve injury. Molecular pain. 2008;4:62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2614976</ArticleId><ArticleId IdType="pubmed">19077191</ArticleId></ArticleIdList></Reference><Reference><Citation>Riedl MS, Braun PD, Kitto KF, Roiko SA, Anderson LB, Honda CN. et al. Proteomic analysis uncovers novel actions of the neurosecretory protein VGF in nociceptive processing. J Neurosci. 2009;29:13377&#x2013;13388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2801058</ArticleId><ArticleId IdType="pubmed">19846725</ArticleId></ArticleIdList></Reference><Reference><Citation>Hannedouche S, Beck V, Leighton-Davies J, Beibel M, Roma G, Oakeley EJ. et al. Identification of the C3a receptor (C3AR1) as the target of the VGF-derived peptide TLQP-21 in rodent cells. The Journal of biological chemistry. 2013;288:27434&#x2013;27443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3779738</ArticleId><ArticleId IdType="pubmed">23940034</ArticleId></ArticleIdList></Reference><Reference><Citation>Fargali S, Garcia AL, Sadahiro M, Jiang C, Janssen WG, Lin WJ. et al. The granin VGF promotes genesis of secretory vesicles, and regulates circulating catecholamine levels and blood pressure. Faseb J. 2014;28:2120&#x2013;2133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3986843</ArticleId><ArticleId IdType="pubmed">24497580</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrott-Fischer A, Bitsche M, Humpel C, Walcher C, Maier H, Jellinger K. et al. Chromogranin peptides in amyotrophic lateral sclerosis. Regulatory peptides. 2009;152:13&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">18721831</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>